Methotrexate bioavailability after oral and subcutaneous administration in children with juvenile idiopathic arthritis

Clinical and Experimental Rheumatology

Volumn 27, Issue 6, 2009, Pages 1047-1053

  Tuková, Jana ^a   Chládek, Jaroslav ^a   Němcová, Dana ^a   Chládková, Jiřina ^a   Doležalová, Pavla ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Bioavailability; Juvenile idiopathic arthritis; Methotrexate; Oral; Subcutaneous

Indexed keywords

FOLIC ACID; HYDROXYCHLOROQUINE; IBUPROFEN; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; GROUPS BY AGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MALE; MORNING DOSAGE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL AVAILABILITY; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; METHOTREXATE; REGRESSION ANALYSIS;

EID: 76649119089     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. CASSIDY JT, PETTY RE: Juvenile Rheumatoid Arthritis. In: CASSIDY JT, PETTY RE (Eds.): Textbook of Pediatric Rheumatology. Philadelphia, WB Saunders 2001: 218-321.
2. GIANNINI EH, BREWER EJ, KUZMINA N, SHAIKOV A, MAXIMOV A, VORONTSOV I: Methotrexate in resistant juvenile rheumatoid arthritis: Results of the U.S.A. - U.S.S.R. Double- blind, placebo- controlled trial. N Engl J Med 1992; 326: 1043-9.
3. WOO P, SOUTHWOOD TR, PRIEUR AM et al.: Randomized, placebo-controlled, crossover trial of low- dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000; 43: 1849-57.
4. FURST DE, KOEHNKE R, BURMEISTER LF, KOHLER J, CARGILL I: Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989; 16: 313-20.
5. BANNWARTH B, PEHOURCQ F, SCHAEVERBEKE T, DEHAIS J: Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996; 30: 194-210.
6. AHERN M, BOOTH J, LOXTON A, MCCARTHY P, MEFFIN P, KEVAT S: Methotrexate kinetics in rheumatoid arthritis: Is there an interaction with nonsteroidal antiinflammatory drugs? J Rheumatol 1988; 15: 1356-60.
7. LEBBE C, BEYELER C, GERBER NJ, REICHEN J: Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 475-7.
8. KREMER JM, PETRILLO GF, HAMILTON RA: Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: Association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J Rheumatol 1995; 22: 38-40.
9. OGUEY D, KOLLIKER F, GERBER NJ, REICHEN J: Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1992; 35: 611-4.
10. HOEKSTRA M, HAAGSMA C, NEEF C, PROOST J, KNUIF A, VAN DE LAAR M: Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 645-8.
11. GODFREY C, SWEENEY K, MILLER K, HAMILTON R, KREMER J: The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Br J Clin Pharmacol 1998; 46: 369-76.
12. SEIDEMAN P, BECK O, EKSBORG S, WENNBERG M: The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. Br J Clin Pharmacol 1993; 35: 409-12.
13. RAVELLI A, FUCCIA GD, MOLINARO M et al.: Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis. J Rheumatol 1993; 20: 1573-7.
14. ALBERTIONI F, FLATO B, SEIDEMAN P et al.: Methotrexate in juvenile rheumatoid arthritis. Eur J Clin Pharmacol 1995; 47: 507-11.
15. KIMURA E, OGA S, PEREIRA RM: Comparative study of the pharmacokinetics of MTX in juvenile idiopathic arthritis patients receiving long-term MTX monotherapy or MTX plus chloroquine. J Clin Pharm Ther 2007; 32: 579-84.
16. WALLACE CA, BLEYER WA, SHERRY DD, SALMONSON KL, WEDGWOOD RJ: Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum 1998; 32: 677-81.
17. PETTY RE, SOUTHWOOD TR, BAUM J et al.: Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998; 25: 1991-4.
18. INTERNATIONAL LEAGUE OF ASSOCIATIONS FOR RHEUMATOLOGY CLASSIFICATION OF JUVENILE IDIOPATHIC ARTHRITIS: Second revision, Edmonton. J Rheumatol 2001; 31: 390-2.
19. GIANNINI EH, RUPERTO N, RAVELLI A, LOVELL DJ, FELSON DT, MARTINI A: Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-9.
20. CHLÁDEK J, MARTÍNKOVÁ J, ŠIMKOVÁ M, VANĚČKOVÁ J: Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment. Eur J Clin Pharmacol 1998; 53: 437-44.
21. WALLACE CA, RUPERTO N, GIANNINI EH: Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31: 2290-4.
22. BALIS FM, MIRRO J, REAMAN GH, EVANS WE, MCCULLY C, DOHERTY KM: Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 1988; 6: 1882-6.
23. LEBBE C, BEYELER C, GERBER NJ, REICHEN J: Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 475-7.
24. KREMER JM, PETRILLO GF, HAMILTON RA: Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J Rheumatol 1995; 22: 38-40.
25. JUNDT JW, BROWNE BA, FIOCCO GP, STEELE AD, MOCK D: A comparison of low dose methotrexate bioavailability: Oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993; 20: 1845-9.
26. HAMILTON RA, KREMER J: Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997; 36: 86-90.
27. BALIS FM, HOLCENBERG JS, POPLACK DG et al.: Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: A joint children's cancer group and pediatric oncology branch study. Blood 1998; 92: 3569-77.
28. TERESI ME, CROMA WR, CHOIA KE, MIRROA J, EVANS WE: Methotrexate bioavailability after oral and intramuscular administration in children. J Pediatr 1987; 110: 788-92.
29. GUIDANCE FOR INDUSTRY: Statistical approaches to establishing bioequivalence. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. January 2001 [updated 2001 August 3; last viewed 2009 January 9]. Available from: http://www. fda.gov/cder/guidance/3616fnl.htm.
30. MARZO A, MONTI NC, VUKSIC D: Experimental, extrapolated and truncated areas under the concentration-time curve in bioequivalence trials. Eur J Clin Pharmacol 1999; 55: 627-31.
31. DALRYMPLE JM, STAMP LK, O'DONNELL JL, CHAPMAN PT, ZHANG M, BARCLAY ML: Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008; 58: 3299-308.
32. ROZIN A, SCHAPIRA D, BALBIR-GURMAN A et al.: Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate. Ann Rheum Dis 2002; 61: 756-7.
33. BRAUN J, KASTNER P, FLAXENBERG P et al.: Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008; 58: 73-81.
34. ALSUFYANI K, VARES OO-A, CABRAL DA, TUCKER LB, PETTY RE, MALLESON PN: The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol 2004; 31: 179-82.
35. BRITISH SOCIETY FOR PAEDIATRIC AND ADOLESCENT RHEUMATOLOGY: BSPAR guidelines on methotrexate use in paediatric rheumatology. 2005 [last viewed 2009 January 9]. Available from: http://www.bspar.org.uk/downloads/ clinical-guidelines/BSPAR-METHR.pdf.
36. NIEHUES T, HORNEFF G, MICHELS H, HOCK MS, SCHUCHMANN L: Evidence-based use of methotrexate in children with rheumatic diseases: A consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria. Rheumatol Int 2005; 25: 169-78.